We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...

BioNTech stock has tumbled since President-elect Donald Trump tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services, but one analyst now sees a buying opportunity.

Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN. Shares of BioNTech fell 4% on Monday.

How Much Money To Invest Now BioNTech stock is building a consolidation with a 131.49 buy point. See if the biotech stock can clear the breakout price in volume at least 40% higher than normal.

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

BioNTech is a Germany-based biotechnology ... It is calculated by dividing the stock price by earnings per share. Value investors look for low P/E ratios that are 15 or lower.

The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the stock from $90.00 to $137.00 in a research report on Friday ...

Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...